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Introduction {#sec006}
============

Non-alcoholic fatty liver disease (NAFLD) causes up to 33% of chronic liver disease worldwide, more than any other cause \[[@pone.0174717.ref001]\]. NAFLD, which has been considered a hepatic manifestation of metabolic syndrome, increases the risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus independently from the traditional risk factors \[[@pone.0174717.ref002]\]. The liver itself releases a variety of proatherogenic, proinflammatory, and diabetogenic mediators such as high-sensitivity C-reactive protein (hsCRP), fibrinogen, and plasminogen activator inhibitor-1 (PAI-1) in subjects with NAFLD \[[@pone.0174717.ref003]\]. Recent studies have shown that hepatokines, predominantly liver-derived and secreted proteins, directly affect glucose and lipid metabolism in a way similar to adipokines and myokines \[[@pone.0174717.ref004],[@pone.0174717.ref005]\].

Leukocyte cell-derived chemotaxin 2 (LECT2) is a 16-kDa secretory protein that was first isolated in 1996 from cultured supernatants of phytohemagglutinin-activated human T-cell leukemia SKW-3 cells \[[@pone.0174717.ref006]\]. Initially, it was identified as a chemotactic factor for neutrophils \[[@pone.0174717.ref006]\]. Later, Lu *et al*. \[[@pone.0174717.ref007]\] showed that LECT2 treatment in mice significantly increased the number of infiltrating polymorphonuclear neutrophils and macrophages into the peritoneum after *Escherichia coli* injection. Furthermore, LECT2 was involved in the pathogenesis of hepatitis by modulation of natural killer T-cells \[[@pone.0174717.ref008]\]. Ovejero *et al*. \[[@pone.0174717.ref009]\] reported that β-catenin-induced LECT2 expression inhibits tumor progression in the liver by suppressing inflammatory and immune responses. Although growing evidence suggests that LECT2 acts as a modulator of immune and inflammatory reactions, few studies have focused on the function of LECT2 in metabolic disorders. Recently, Lan *et al*. \[[@pone.0174717.ref010]\] redefined LECT2 as a novel hepatokine that mediates obesity with skeletal muscle insulin resistance. In that study, genetic deletion of LECT2 in mice increased insulin sensitivity in skeletal muscle, but treatment with recombinant LECT2 protein impaired insulin signaling via phosphorylation of Jun NH2-terminal kinase (JNK) in myocytes. They also showed that the expression of the genes involved in mitochondria and myogenesis was up-regulated in the muscle of LECT^-/-^ mice \[[@pone.0174717.ref010]\], emphasizing the pivotal role of LECT2 on the provocation of peripheral insulin resistance. Recently, we reported that a dipeptidyl peptidase 4 inhibitor improves hepatic steatosis as well as insulin resistance through AMP-activated protein kinase (AMPK)- and JNK-dependent inhibition of LECT2 expression \[[@pone.0174717.ref011]\]. Furthermore, we found that LECT2 induces pro-inflammatory cytokines and adhesion molecules via CD209 receptor-mediated JNK phosphorylation in human umbilical vein endothelial cells (HUVECs) \[[@pone.0174717.ref012]\]. However, there have been very limited studies to examine the clinical significance of circulating LECT2 levels in metabolic diseases including NAFLD and atherosclerosis in humans.

Therefore, we evaluated whether circulating levels of LECT2 are increased in the subjects with NAFLD and exhibit significant correlations with various components of metabolic syndrome as well as systemic low-grade inflammatory status, represented as high sensitivity C-reactive protein (hsCRP) and subclinical atherosclerosis measured using carotid intima-media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV).

Subjects and methods {#sec007}
====================

Study design and participants {#sec008}
-----------------------------

Our group had collected the anthropometric and laboratory data as well as blood samples from participants among individuals who were self-referred for a routine health check-up at the Health Promotion Center of Korea University Guro Hospital, between April 2012 and July 2014. All participants provided written informed consent, and the Korea University Institutional Review Board approved this study protocol in accordance with the Declaration of Helsinki of the World Medical Association. From the baseline samples of these cohort subjects (n = 1,128), we randomly selected NAFLD group (n = 160) and age, sex-matched control group (n = 160) based on the inclusion and exclusion criteria. We had included participants who are agreed to participate in our study and subjects had been excluded if they met any of the following criteria: history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization); stage 2 hypertension (resting blood pressure, ≥160/100 mmHg); history of inflammatory conditions that could affect the study results; taking medications that might affect inflammatory status including steroid and non-steroidal anti-inflammatory drugs within six months; hepatic malignancy; or severe renal or hepatic disease. To avoid cofounding variables associated with NAFLD, participants were additionally excluded for this study if they exhibited: consumption of \>140 g alcohol/week \[[@pone.0174717.ref013]\], a positive test for hepatitis B surface antigen or hepatitis C antibody, or use of herbal medication within 6 months. In this study, NAFLD was diagnosed on ultrasonography by a single experienced radiologist who was blinded to the anthropometric and laboratory data. Metabolic syndrome was defined according to criteria established by the National Cholesterol Education Program Adult Treatment Panel III (NCEP III) using the adjusted waist circumference for Asians \[[@pone.0174717.ref014]\]. The criteria require the presence of three or more of the following components: 1) high blood pressure (systolic blood pressure ≥ 130, diastolic blood pressure ≥85 mmHg, or known treatment for hypertension), 2) hypertriglyceridemia (fasting plasma triglycerides ≥1.69 mmol/L), 3) low high density lipoprotein cholesterol (HDL-C) (fasting HDL-C \<1.04 mmol/L in men, \<1.29 mmol/L in women), and 4) hyperglycemia (fasting plasma glucose ≥5.6 mmol/L or known treatment for diabetes). Medical histories and lifestyle information were collected for all subjects by personal interview using a detailed questionnaire.

Anthropometric and laboratory measurements {#sec009}
------------------------------------------

Body mass index (BMI) was calculated as weight/height^2^ (kg/m^2^) and waist circumference was measured at the midpoint between the lower border of the rib cage and the iliac crest. All blood samples were obtained in the morning after a 12-hour overnight fast, and were immediately stored at -80°C for subsequent analyses. Serum triglyceride and HDL-C levels were determined enzymatically using a model 747 chemistry analyzer (Hitachi, Tokyo, Japan). The glucose oxidase method was used to measure plasma glucose levels. Latex-enhanced turbidimetric immunoassay (HiSens hsCRP LTIA; HBI, Anyang, Korea) was used for measurement of hsCRP with an inter-assay coefficient of variation of 7.2%. Plasma LECT2 levels were assayed using a commercially available ELISA (MBL, Nagoya, Japan); the intra-assay variations were 2.2--3.2%

Measurement of baPWV {#sec010}
--------------------

After subjects rested in the supine position for 5 minutes, baPWV was measured using a volume-plethysmographic apparatus (model BP-203RPE II; Colin, Komaki, Japan) that simultaneously recorded baPWV and brachial and ankle blood pressures on the left and right sides. The details of this method, including validity and reproducibility, were described previously \[[@pone.0174717.ref015]\]. The intra- and inter-observer reproducibility of this method in the present study was 10.0% and 8.4%, respectively. The baPWV was calculated as the mean of the left and right baPWV values.

Measurement of carotid IMT {#sec011}
--------------------------

The IMT of the common carotid artery was determined using high-resolution B-mode ultrasonography (EnVisor; Philips Medical Systems, Andover, MA, USA) with a 5-12-MHz transducer. Measurements of the carotid IMT were made using IMT measurement software (Intimascope; Media Cross Co., Tokyo, Japan) at three levels of the lateral walls of the carotid artery, 1--3 cm proximal to the carotid bifurcation. The mean carotid IMT was the mean value of the mean left and right IMT measurements.

Statistical analysis {#sec012}
--------------------

We performed the Shapiro--Wilk test to evaluate the normality of continuous variables. As a result of normality test, all data are expressed as a median (inter-quartile range \[25%, 75%\]) for continuous variables or N (%) for categorical variables. Differences among the groups were tested using the Mann-Whitney test for continuous variables or Pearson's chi-square test for categorical variables. Spearman's correlation coefficient was used to evaluate the correlations of serum LECT2 levels with metabolic risk factors. Multiple logistic regression analysis was performed to identify whether quartiles of circulating LECT2 levels could influence the risk of NAFLD even after adjusting for other confounding factors. All statistical results were based on two-sided tests. Data was analyzed using SAS 9.4 (SAS Institute, Cary, NC, USA). P-values \<0.05 were considered statistically significant.

Results {#sec013}
=======

Baseline characteristic of subjects with or without NAFLD {#sec014}
---------------------------------------------------------

The clinical and biochemical characteristics of the study subjects are presented in [Table 1](#pone.0174717.t001){ref-type="table"}. Subjects with NAFLD showed a significantly higher BMI, waist circumference, systolic blood pressure, white blood cell (WBC) count, albumin concentration, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentration, hsCRP, fasting glucose level, and triglyceride level compared to the control group. In contrast, HDL-C level in the NAFLD group was significantly lower than in the control group. In particular, plasma LECT2 levels in the NAFLD group were significantly higher than the subjects without NAFLD (31.2 \[20.9, 41.5\] vs. 24.5\[16.3, 32.7\] ng/ml, *P* \<0.001) ([Fig 1](#pone.0174717.g001){ref-type="fig"}).

10.1371/journal.pone.0174717.t001

###### Baseline characteristics of study subjects.

![](pone.0174717.t001){#pone.0174717.t001g}

  --------------------------------------------------------------------------------------
                              Subjects without NAFLD\   Subjects with NAFLD\   *P*
                              (n = 160)                 (n = 160)              
  --------------------------- ------------------------- ---------------------- ---------
  Age (years)                 52.5 (46.5, 56.5)         52.5 (47.0, 57.0)      0.910

  Sex (M:F)                   104:56                    104:56                 1.000

  BMI (kg/m^2^)               23.1 (21.5, 25.0)         25.6 (23.9, 27.9)      \<0.001

  Waist circumference (cm)    78 (72.5, 84)             85 (81, 91)            \<0.001

  Current smoker (%)          36 (22.5)                 36 (22.5)              1.000

  Alcohol consumption (%)     95 (59.4)                 79 (49.4)              0.073

  Systolic BP (mmHg)          116 (106, 127)            118 (111, 129.5)       0.016

  Diastolic BP (mmHg)         76 (70, 84)               78 (70, 87)            0.184

  Hemoglobin (g/dL)           14.4 (13.1, 15.1)         14.4 (13.5, 15.3)      0.246

  WBC (10^3^/μL)              5.4 (4.4, 6.5)            6.0 (5.2, 7.0)         \<0.001

  Platelet count (10^3^/μL)   204 (181.0, 237.5)        220.5 (188.5, 245.0)   0.028

  BUN (mg/dL)                 13.7 (11.9, 16.6)         15.1 (12.5, 17.4)      0.045

  Creatinine (mg/dL)          0.78 (0.62, 0.86)         0.79 (0.64, 0.91)      0.159

  Total bilirubin (mg/dL)     0.74 (0.61, 0.99)         0.72 (0.56, 0.93)      0.373

  Albumin (g/dL)              4.4 (4.2, 4.5)            4.4 (4.3, 4.5)         0.001

  AST (IU/L)                  23 (20, 31)               27 (22, 37)            \<0.001

  ALT (IU/L)                  19 (15, 26)               30 (20, 42)            \<0.001

  hsCRP (mg/dL)               0.5 (0.2, 1.4)            0.9 (0.4, 2.2)         0.003

  Glucose (mmol/L)            5.22 (4.94, 5.61)         5.55 (5.19, 6.05)      \<0.001

  LDL cholesterol (mmol/L)    3.15 (2.64, 3.83)         3.10 (2.59, 3.85)      0.703

  HDL cholesterol (mmol/L)    1.40 (1.16, 1.73)         1.22 (1.03, 1.40)      \<0.001

  Triglyceride (mmol/L)       0.99 (0.67, 1.54)         1.57 (1.03, 2.25)      \<0.001

  Mean baPWV (m/sec)          13.11 (12.01, 14.35)      13.34 (12.38, 14.75)   0.171

  Mean CIMT (mm)              0.65 (0.58, 0.72)         0.67 (0.61, 0.73)      0.061
  --------------------------------------------------------------------------------------

NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; BP, blood pressure; WBC, white blood cell; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; baPWV, brachial-ankle pulse wave velocity; CIMT, carotid intima-media thickness. *P*-values represent the results of a Mann-Whitney test or Pearson's Chi-square test, which were conducted to detect differences between the two groups.

![Comparison of circulating leukocyte cell-derived chemotaxin 2 (LECT2) concentrations in the subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) vs. those without NAFLD (31.2 \[20.9, 41.5\] vs. 24.5 \[16.3, 32.7\] ng/ml, *P* \<0.001).\
*P*-values represent the results of a Mann-Whitney test that was conducted to detect differences between the two groups.](pone.0174717.g001){#pone.0174717.g001}

Correlation of circulating LECT2 concentrations with metabolic risk factors {#sec015}
---------------------------------------------------------------------------

Plasma LECT2 levels had significant positive correlations with BMI, waist circumference, hemoglobin, creatinine, albumin, AST, ALT, LDL cholesterol (LDL-C), triglyceride and hsCRP levels and a significant negative correlation with HDL-C in the total subjects ([Table 2](#pone.0174717.t002){ref-type="table"}). In addition, circulating LECT2 level had a significant positive correlation with the number of metabolic syndrome components in the total subjects. Interestingly, although circulating LECT2 concentrations were significantly correlated with various metabolic risk factors in the subjects with NAFLD, plasma LECT2 levels were not significantly correlated with most of the metabolic risk factors in subjects without NAFLD; two exceptions were serum albumin and ALT levels. Furthermore, plasma LECT2 levels exhibited no significant association with mean CIMT or baPWV values both in control and NAFLD groups. We reclassified total subjects into the subjects with metabolic syndrome (n = 96) and without metabolic syndrome (n = 224). As a result, LECT2 concentrations in the subjects with metabolic syndrome were significantly higher than the subjects without metabolic syndrome (32.6 \[17.8, 45.0\] vs. 27.0 \[18.7, 33.7\] ng/ml, *P* = 0.016) ([Fig 2](#pone.0174717.g002){ref-type="fig"}).

10.1371/journal.pone.0174717.t002

###### Spearman correlation coefficients for the relationship between circulating LECT2 levels and various metabolic risk factors.
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                              Total   Subjects without NAFLD   Subjects with NAFLD                   
  --------------------------- ------- ------------------------ --------------------- ------- ------- -------
  Age                         -0.09   0.103                    -0.08                 0.307   -0.11   0.156
  Sex                         0.07    0.225                    0.00                  0.983   0.15    0.061
  BMI                         0.23    \<.0001                  0.14                  0.073   0.18    0.024
  Waist circumference         0.24    \<.0001                  0.11                  0.157   0.21    0.007
  Systolic BP (mmHg)          0.09    0.090                    -0.03                 0.748   0.16    0.041
  Diastolic BP (mmHg)         0.11    0.056                    0.00                  0.973   0.18    0.020
  Hemoglobin                  0.15    0.009                    0.12                  0.134   0.17    0.030
  WBC                         0.06    0.318                    0.01                  0.855   0.00    0.952
  Platelet count              0.02    0.686                    -0.01                 0.942   0.01    0.900
  BUN                         0.05    0.345                    0.08                  0.307   -0.02   0.797
  Creatinine                  0.15    0.008                    0.11                  0.163   0.15    0.051
  Total bilirubin             0.05    0.337                    0.05                  0.531   0.08    0.308
  Albumin                     0.17    0.003                    0.22                  0.006   0.06    0.460
  AST                         0.12    0.037                    0.1                   0.231   0.04    0.585
  ALT                         0.19    0.001                    0.19                  0.015   0.03    0.731
  hsCRP                       0.16    0.004                    0.06                  0.448   0.20    0.009
  Glucose                     0.07    0.204                    -0.06                 0.444   0.08    0.306
  LDL cholesterol             0.12    0.035                    0.04                  0.592   0.20    0.013
  HDL cholesterol             -0.17   0.002                    -0.08                 0.333   -0.16   0.050
  Triglycerides               0.16    0.003                    0.03                  0.720   0.15    0.060
  Number of MetS components   0.13    0.018                    -0.05                 0.551   0.15    0.055
  Mean baPWV                  0.02    0.745                    -0.03                 0.665   0.03    0.704
  Mean CIMT                   0.04    0.461                    -0.01                 0.934   0.04    0.645

NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; BP, blood pressure; WBC, white blood cell; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; MetS, metabolic syndrome; baPWV, brachial-ankle pulse wave velocity; CIMT, carotid intima-media thickness. *P*-values represent the results of Spearman's correlation analysis.

![Comparison of circulating leukocyte cell-derived chemotaxin 2 (LECT2) concentrations in the subjects with metabolic syndrome (n = 96) vs. those without metabolic syndrome (n = 224) (32.6 \[17.8, 45.0\] vs. 27.0 \[18.7, 33.7\] ng/ml, *P* = 0.016).\
*P*-values represent the results of a Mann-Whitney test that was conducted to detect differences between the two groups.](pone.0174717.g002){#pone.0174717.g002}

The odds ratio for NAFLD according to quartile of circulating LECT2 levels {#sec016}
--------------------------------------------------------------------------

Univariate and multivariate logistic regression analysis was used to assess the odd ratios (OR) of NAFLD across the quartiles of plasma LECT2 concentrations ([Table 3](#pone.0174717.t003){ref-type="table"}). In an unadjusted model, the OR for NAFLD was 2.51 (95% CI, 1.22--5.19) in the highest quartile of plasma LECT2 levels when compared to that of the lowest. After controlling for age, sex, AST, ALT, total bilirubin, systolic blood pressure, serum glucose and hsCRP levels (model 3), the significance of the association between plasma LECT2 levels and NAFLD persisted (*P* for linear trend = 0.028); the OR in the highest quartile of circulating LECT2 level for NAFLD was 2.38 (95% CI, 1.06--5.37) when compared to that of the lowest. However, after further adjustment for serum triglyceride, HDL-C, LDL-C levels and waist circumference (model 5), the statistical significance between circulating LECT2 and NAFLD was attenuated (*P* for linear trend = 0.165).

10.1371/journal.pone.0174717.t003

###### Odds ratios for NAFLD according to circulating LECT2 quartiles.
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                               Q1            Q2                  Q3                  Q4                  *P* for linear trend
  ---------------------------- ------------- ------------------- ------------------- ------------------- ----------------------
  Number of cases/references   15/65         15/65               21/60               29/50               
  LECT2 (range, ng/ml)         2.89--18.68   18.70--27.21        27.29--36.80        37.46--76.42        
  Univariate                   1             1.00 (0.45, 2.21)   1.52 (0.72, 3.21)   2.51 (1.22, 5.19)   0.006
  Multivariate                                                                                           
  Model 1                      1             1.00 (0.45, 2.22)   1.52 (0.72, 3.22)   2.57 (1.24, 5.33)   0.005
  Model 2                      1             1.24 (0.52, 2.92)   1.60 (0.71, 3.61)   2.50 (1.13, 5.53)   0.017
  Model 3                      1             1.23 (0.51, 2.95)   1.62 (0.71, 3.71)   2.38 (1.06, 5.37)   0.028
  Model 4                      1             1.34 (0.54, 3.31)   1.46 (0.62, 3.44)   2.20 (0.94, 5.15)   0.076
  Model 5                      1             1.23 (0.48, 3.13)   1.32 (0.55, 3.14)   1.86 (0.78, 4.43)   0.165

AST, aspartate transaminase; ALT, alanine transaminase; SBP, systolic blood pressure; hsCRP, high-sensitivity C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Model 1: Adjusting for age and sex. Model 2: age, sex, AST, ALT and total bilirubin. Model 3: age, sex, AST, ALT, total bilirubin, SBP, glucose and hsCRP. Model 4: age, sex, AST, ALT, total bilirubin, SBP, glucose, hsCRP, triglyceride, HDL and LDL cholesterol. Model 5: age, sex, AST, ALT, total bilirubin, SBP, glucose, hsCRP, triglyceride, HDL, LDL cholesterol and waist circumference. *P*-values represent the results of multiple logistic regression analysis.

Discussion {#sec017}
==========

The present study shows that circulating LECT2, which has been recently redefined as a hepatokine, is significantly higher in subjects with NAFLD and/or metabolic syndrome compared to those without NAFLD and metabolic syndrome. Furthermore, plasma LECT2 levels had significant positive correlations with various metabolic risk factors including abdominal obesity, adverse lipid profiles, and low-grade systemic inflammatory status.

Inflamed visceral adipose tissue is the main source of an elevated flux of free fatty acids into the portal vein for direct transport to the liver and subsequent hepatic fat accumulation \[[@pone.0174717.ref016]\]. This means that NAFLD is a sensitive marker for pathological accumulation of visceral fat. Meanwhile, hepatic steatosis itself leads to endoplasmic reticulum (ER) stress, leading to activation JNK and nuclear factor κB (NFκB), two major regulators of inflammatory pathways that exacerbate insulin resistance both locally in the liver and systemically \[[@pone.0174717.ref002]\]. Therefore, the liver can function as an inducer of systemic inflammation as well as a target of various inflammatory reactions that occur with dysfunctional adipose tissue. Hepatokines, which are exclusively secreted by the liver, directly affect energy metabolism by modulating insulin signaling and inflammatory cascades \[[@pone.0174717.ref017]\]. In a recent clinical trial, treatment with an analog of fibroblast growth factor 21 (FGF21), a representative hepatokine, produced significant improvements in dyslipidemia in humans with obesity and type 2 diabetes \[[@pone.0174717.ref018]\]. Previously, we showed a significant decrease in circulating fetuin-A level, which was the first hepatokine discovered, after 12 weeks of caloric restriction. This decrease in fetuin-A was accompanied by improvements in visceral fat area, blood pressure, lipid profiles, and glucose levels \[[@pone.0174717.ref019]\]. These results suggest that the changes in circulating hepatokines might be associated with the beneficial effects of caloric restriction. Therefore, discovery of novel hepatokines may provide profound insight and promising therapeutic targets for NAFLD-related metabolic disturbances including type 2 diabetes and CVD.

LECT2 is a recently discovered hepatokine that contributes to the development of skeletal muscle insulin resistance in obesity \[[@pone.0174717.ref010]\]. In a study by Lan *et al*., a treadmill running challenge revealed that muscle endurance was significantly higher in LECT2^-/-^ mice \[[@pone.0174717.ref010]\]. In addition, C2C12 myocytes transfected with the LECT2 vector showed a significant decrease in insulin-stimulated Akt phosphorylation and an increase in basal JNK phosphorylation \[[@pone.0174717.ref010]\]. Furthermore, a double knockdown of JNK1 and JNK2 rescued the cells from the inhibitory effects of LECT2 on insulin signaling \[[@pone.0174717.ref010]\]. Likewise, we previously showed that the level of phosphorylated JNK was significantly increased by LECT2 treatment in HUVEC and THP-1 cells \[[@pone.0174717.ref012]\]. Considering that the JNK signaling pathway plays a crucial role in diverse metabolic responses to inflammation \[[@pone.0174717.ref020]\], LECT2, which activates the JNK pathway, might be involved in the various metabolic disturbances in humans. However, very few studies have explored the clinical relevance of circulating LECT2 levels in humans.

Lan *et al*. \[[@pone.0174717.ref010]\] found a significant positive correlation between plasma LECT2 levels and BMI, waist circumference, and homeostasis model assessment of insulin resistance (HOMA-IR). Also, Okumura *et al*. \[[@pone.0174717.ref021]\] used receiver operating characteristics (ROC) curve analysis and showed that plasma LECT2 levels efficiently discriminated between subjects with and without fatty livers. However, the relationship between LECT2 and NAFLD that they reported did not adjust for potential confounding factors. In the present study, subjects with NAFLD had significantly higher circulating LECT2 levels when compared to subjects without NAFLD. Furthermore, the OR for NAFLD was 2.38 (95% CI, 1.06--5.37) in the highest quartile of serum LECT2 levels when compared to that of the lowest quartile even after adjusting for other covariates including age, sex, AST, ALT, total bilirubin, systolic blood pressure, serum glucose and hsCRP levels. However, the statistical significance was attenuated after adjusting for serum triglyceride, HDL-C, LDL-C levels and waist circumference, suggesting that LECT2 might be associated with the development of NAFLD through mediation of dyslipidemia and abdominal obesity. Indeed, the present study revealed that LECT2 levels are significantly higher in patients with metabolic syndrome compared to those without metabolic syndrome.

Previously, we demonstrated that LECT2 increased mammalian target of rapamycin (mTOR) phosphorylation, sterol regulatory element-binding protein (SREBP)-1 cleavage, lipid accumulation, and insulin resistance in HepG2 cells \[[@pone.0174717.ref011]\]. Furthermore, in our previous research, LECT2 treatment efficiently increased the expression of adhesion molecules and pro-inflammatory cytokines in HUVECs and THP-1 cells \[[@pone.0174717.ref012]\], suggesting the possibility that LECT2 might directly mediate atherosclerotic inflammatory reactions in human endothelial cells. In fact, monocyte chemoattractant protein-1 (MCP-1), a C-C chemokine, and its receptor, C-C chemokine receptor-2 (CCR2), are known to play an important role in atherogenesis \[[@pone.0174717.ref022],[@pone.0174717.ref023]\]. Furthermore, accumulated evidence has demonstrated that NAFLD is an independent risk factor for CVD \[[@pone.0174717.ref024]\]. In a study of 15,913 Korean adults, greater severity of NAFLD showed a higher correlation with estimated 10-year CVD risk \[[@pone.0174717.ref025]\]. However, the present clinical study showed no significant association between circulating LECT2 levels and subclinical atherosclerosis measured by CIMT and baPWV values. The exact reason for this discrepancy between animal and human studies is not clear, and further study is needed to explore the relationship between LECT2 and atherosclerosis. Instead, we found that plasma LECT2 levels had a significant positive correlation with circulating hsCRP levels, a representative systemic inflammatory marker in subjects with NAFLD, but not in those without NAFLD. Many previous studies have shown that increased hsCRP levels are associated with an increased risk of CV events even after adjustment for traditional risk factors \[[@pone.0174717.ref026]\]. Similarly, there were significant correlations between circulating LECT2 levels and various metabolic risk factors in subjects with NAFLD, but not in subjects without NAFLD. Lan *et al*. \[[@pone.0174717.ref010]\] showed that LECT2 plays a major role in the regulation of insulin sensitivity under excess caloric conditions, but not under restricted caloric conditions. Therefore, LECT2 may be associated with metabolic disturbances and unfavorable clinical consequences in individuals with obesity and NAFLD.

The present study has several limitations. First, due to the inherent limitations of a cross-sectional study design, no definite conclusions about causality between circulating LECT2 levels and the development of NAFLD or metabolic syndrome can be drawn. Secondly, only relatively healthy Asian men and women were enrolled in this study, so the results of the current study should be further evaluated in other ethnic populations. Thirdly, we diagnosed NAFLD using ultrasonography. Although liver biopsy is a gold standard for the diagnosis of NAFLD, it is not feasible in epidemiologic studies including large numbers of participants due to its invasiveness. Lastly, this study could not clarify the functional mechanisms of LECT2 on the inflammatory process.

In conclusion, circulating LECT2 levels were significantly associated with NAFLD and metabolic syndrome mainly by mediating dyslipidemia and abdominal obesity. Further large--scaled prospective studies and the experimental studies to explore the mechanistic pathways and functional roles of LECT2 as a novel hepatokine are warranted.
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hsCRP

:   high sensitivity C-reactive protein
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:   Jun NH2-terminal kinase
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